Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Esperion Therapeutics, Inc. - Common Stock
(NQ:
ESPR
)
4.040
+0.090 (+2.28%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 26, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Esperion Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes
December 19, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
December 09, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Therapeutics Stock Hits Near 1-Year High As Wall Street Sees Strong Risk-Reward Play On Demand For Cholesterol Drug
↗
November 25, 2025
Piper Sandler projected long-term growth backed by rising use of Esperion’s LDL-lowering therapies and expanding payer coverage.
Via
Stocktwits
Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
November 21, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Earnings Scheduled For November 6, 2025
↗
November 06, 2025
Via
Benzinga
Why Is Esperion Therapeutics Stock Sinking Premarket Today?
↗
October 08, 2025
Via
Stocktwits
Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference
November 19, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
November 18, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025
November 10, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 06, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
DoorDash Posts Downbeat Q3 Earnings, Joins elf Beauty, Duolingo, HubSpot And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
↗
November 06, 2025
Via
Benzinga
Esperion Therapeutics Inc (NASDAQ:ESPR) Reports Mixed Q3 2025 Results with Revenue Beat and Wider Loss
↗
November 06, 2025
Esperion's Q3 2025 shows strong revenue growth beating estimates, but a deeper loss led to a sharp stock sell-off. The company secured key patents and targets profitability in 2026.
Via
Chartmill
Topics
Intellectual Property
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
November 06, 2025
Via
Benzinga
Why Snap Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
↗
November 06, 2025
Via
Benzinga
Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update
November 06, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer
November 04, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in Jefferies Global Healthcare Conference - London
November 03, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET.
October 28, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025
October 27, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Report Third Quarter 2025 Financial Results on November 6
October 23, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis
October 16, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Dow Jumps Over 100 Points; US Crude Oil Inventories Increase
↗
October 08, 2025
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
October 08, 2025
Via
Benzinga
These stocks that are showing activity before the opening bell on Wednesday.
↗
October 08, 2025
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
October 08, 2025
Via
Benzinga
Penguin Solutions Posts Q4 Earnings, Joins Esperion Therapeutics, Joby Aviation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
↗
October 08, 2025
Via
Benzinga
Why Confluent Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
↗
October 08, 2025
Via
Benzinga
Esperion Announces Pricing of Public Offering of Common Stock
October 07, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
October 07, 2025
Via
Benzinga
Curious about the stocks that are showing activity after the closing bell on Tuesday?
↗
October 07, 2025
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
